{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:47:06Z","timestamp":1793278026939,"version":"4.5.0"},"reference-count":33,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"NIH","doi-asserted-by":"publisher","award":["R01NS083795"],"award-info":[{"award-number":["R01NS083795"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NIH","doi-asserted-by":"publisher","award":["R01NS113793"],"award-info":[{"award-number":["R01NS113793"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NIH","doi-asserted-by":"publisher","award":["R21NS137660"],"award-info":[{"award-number":["R21NS137660"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NIH","doi-asserted-by":"publisher","award":["R01NS072050"],"award-info":[{"award-number":["R01NS072050"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"award":["R01NS083795"],"award-info":[{"award-number":["R01NS083795"]}],"id":[{"id":"https:\/\/ror.org\/044zkrt47","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01NS113793"],"award-info":[{"award-number":["R01NS113793"]}],"id":[{"id":"https:\/\/ror.org\/044zkrt47","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R21NS137660"],"award-info":[{"award-number":["R21NS137660"]}],"id":[{"id":"https:\/\/ror.org\/044zkrt47","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01NS072050"],"award-info":[{"award-number":["R01NS072050"]}],"id":[{"id":"https:\/\/ror.org\/044zkrt47","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Dpep is a cell-penetrating peptide that targets transcription factors ATF5, CEBPB and CEBPD to selectively suppress growth and survival of diverse tumor cell types in vitro and in vivo. Due to these actions and its apparent safety, the peptide has potential as a cancer therapeutic. How Dpep might be combined with other anti-cancer agents to achieve synergistic efficacy and to overcome possible peptide resistance has not been assessed in depth. Based on prior work indicating that Dpep promotes apoptotic cancer cell death and up-regulates multiple pro-apoptotic and tumor suppressor genes, we studied combinations of Dpep with ABT-263, a pro-apoptotic BCL2 family inhibitor, and decitabine, a hypomethylating drug. Combining Dpep with each agent alone or together synergistically suppressed the growth of a range of solid and liquid tumor cell types. Moreover, the combinations synergistically inhibited the growth of cells lines that were selected either in vivo or in vitro for Dpep resistance. Finally, we tested the combination of Dpep with ABT-263 in a mouse melanoma xenograft model. The combination more effectively inhibited tumor growth than either agent alone and, in contrast to vehicle or ABT-263, produced a 40% durable survival rate. Taken together, these observations highlight potential drug partners for the therapeutic development of Dpep.<\/jats:p>","DOI":"10.3390\/cells15090826","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:15:27Z","timestamp":1777630527000},"page":"826","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dpep, a Cell-Penetrating Peptide Targeting ATF5, CEBPB and CEBPD, Synergistically Combines with ABT-263 and Decitabine to Inhibit Cancer Cell Growth and Overcome Dpep Resistance"],"prefix":"10.3390","volume":"15","author":[{"given":"Qing","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8747-9082","authenticated-orcid":false,"given":"Trang Thi Thu","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA"},{"name":"Ronald O. Perelman Department of Dermatology, Perlmutter Cancer Center, NYU Grossman School of Medicine, NYU Langone Health, New York, NY 10016, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5612-1221","authenticated-orcid":false,"given":"James M.","family":"Angelastro","sequence":"additional","affiliation":[{"name":"Department of Molecular Biosciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus D.","family":"Siegelin","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-5521","authenticated-orcid":false,"given":"Lloyd A.","family":"Greene","sequence":"additional","affiliation":[{"name":"Department of Pathology and Cell Biology, Vagelos College of Physicians & Surgeons, Columbia University Irving Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1007\/s12672-025-04122-6","article-title":"CEBPB Emerges as a Key Regulatory Factor in Human Cancers through Diverse Molecular Mechanisms and Clinical Implications","volume":"16","author":"He","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Paerhati, P., Liu, J., Jin, Z., Jako\u0161, T., Zhu, S., Qian, L., Zhu, J., and Yuan, Y. (2022). Advancements in Activating Transcription Factor 5 Function in Regulating Cell Stress and Survival. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137129"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.trecan.2017.05.004","article-title":"Targeting ATF5 in Cancer","volume":"3","author":"Angelastro","year":"2017","journal-title":"Trends Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"103983","DOI":"10.1016\/j.critrevonc.2023.103983","article-title":"The Dual Role of C\/EBP\u03b4 in Cancer","volume":"185","author":"Hartl","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Greene, L.A., Zhou, Q., Siegelin, M.D., and Angelastro, J.M. (2023). Targeting Transcription Factors ATF5, CEBPB and CEBPD with Cell-Penetrating Peptides to Treat Brain and Other Cancers. Cells, 12.","DOI":"10.3390\/cells12040581"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1158\/1078-0432.CCR-15-2827","article-title":"A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers","volume":"22","author":"Horst","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1158\/1541-7786.MCR-19-0631","article-title":"Dominant-Negative ATF5 Compromises Cancer Cell Survival by Targeting CEBPB and CEBPD","volume":"18","author":"Sun","year":"2020","journal-title":"Mol. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Sun, X., Pasquier, N., Jefferson, P., Nguyen, T.T.T., Siegelin, M.D., Angelastro, J.M., and Greene, L.A. (2021). Cell-Penetrating CEBPB and CEBPD Leucine Zipper Decoys as Broadly Acting Anti-Cancer Agents. Cancers, 13.","DOI":"10.3390\/cancers13102504"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1126\/science.1233465","article-title":"Networks of bZIP Protein-Protein Interactions Diversified over a Billion Years of Evolution","volume":"340","author":"Reinke","year":"2013","journal-title":"Science"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1101\/gad.7.6.1047","article-title":"Dimerization Specificity of the Leucine Zipper-Containing bZIP Motif on DNA Binding: Prediction and Rational Design","volume":"7","author":"Vinson","year":"1993","journal-title":"Genes. Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"12718","DOI":"10.18632\/oncotarget.7212","article-title":"Regression\/Eradication of Gliomas in Mice by a Systemically-Deliverable ATF5 Dominant-Negative Peptide","volume":"7","author":"Cates","year":"2016","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1158\/2767-9764.CRC-23-0154","article-title":"Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance","volume":"3","author":"Banerjee","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Siegelin, M.D., and Greene, L.A. (2025). Targeting ATF5, CEBPB, and CEBPD with Cell-Penetrating Dpep Sensitizes Tumor Cells to NK-92MI Cell Cytotoxicity. Cells, 14.","DOI":"10.20944\/preprints202503.1611.v1"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Zhou, Q., and Greene, L.A. (2023). Dpep Inhibits Cancer Cell Growth and Survival via Shared and Context-Dependent Transcriptome Perturbations. Cancers, 15.","DOI":"10.3390\/cancers15225318"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Zhou, Q., Nguyen, T.T.T., Mun, J.-Y., Siegelin, M.D., and Greene, L.A. (2024). DPEP Inhibits Cancer Cell Glucose Uptake, Glycolysis and Survival by Upregulating Tumor Suppressor TXNIP. Cells, 13.","DOI":"10.20944\/preprints202405.0846.v1"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41419-019-1872-y","article-title":"Dominant-Negative ATF5 Rapidly Depletes Survivin in Tumor Cells","volume":"10","author":"Sun","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00280-025-04760-1","article-title":"A Phase 1 Study of the Combination of BH3-Mimetic, Navitoclax, and mTORC1\/2 Inhibitor, Vistusertib, in Patients with Advanced Solid Tumors","volume":"95","author":"Scott","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1007\/s12094-022-03070-9","article-title":"Bcl-2 Pathway Inhibition in Solid Tumors: A Review of Clinical Trials","volume":"25","author":"Ploumaki","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Nor Hisam, N.S., Ugusman, A., Rajab, N.F., Ahmad, M.F., Fenech, M., Liew, S.L., and Mohamad Anuar, N.N. (2021). Combination Therapy of Navitoclax with Chemotherapeutic Agents in Solid Tumors and Blood Cancer: A Review of Current Evidence. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091353"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Xu, J., Dong, X., Huang, D.C.S., Xu, P., Zhao, Q., and Chen, B. (2023). Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers. Cancers, 15.","DOI":"10.3390\/cancers15204957"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Scandolara, T.B., Siqueira, I.V.M., Ribeiro Pinto, L.F., and Soares-Lima, S.C. (2025). The Power and the Promise of Epigenetic Drugs in Oncology. Front. Genet., 16.","DOI":"10.3389\/fgene.2025.1622115"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.70197","article-title":"DNA Methyltransferase Inhibitors in Hematological Malignancies and Solid Tumors","volume":"158","author":"Wenger","year":"2026","journal-title":"Int. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"189066","DOI":"10.1016\/j.bbcan.2023.189066","article-title":"Epigenetic Therapy: Research Progress of Decitabine in the Treatment of Solid Tumors","volume":"1879","author":"Ye","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"107652","DOI":"10.1016\/j.bioorg.2024.107652","article-title":"Targeting DNA Methyltransferases for Cancer Therapy","volume":"151","author":"Wang","year":"2024","journal-title":"Bioorg. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-23-0842","article-title":"A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine\/Venetoclax in MDS and AML","volume":"29","author":"Levitz","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-022-01295-3","article-title":"Clinical Experiences with Venetoclax and Other Pro-Apoptotic Agents in Lymphoid Malignancies: Lessons from Monotherapy and Chemotherapy Combination","volume":"15","author":"Lew","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/s41419-025-08040-x","article-title":"The Combination of Venetoclax with Dimethyl Fumarate Synergistically Induces Apoptosis in AML Cells by Disrupting Mitochondrial Integrity through ROS Accumulation","volume":"16","author":"Kawaguchi","year":"2025","journal-title":"Cell. Death Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2010.31.6208","article-title":"Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients with Small-Cell Lung Cancer and Other Solid Tumors","volume":"29","author":"Gandhi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1868-7083-5-3","article-title":"Pharmacokinetic and Pharmacodynamic Analysis of 5-Aza-2\u2032-Deoxycytidine (Decitabine) in the Design of Its Dose-Schedule for Cancer Therapy","volume":"5","author":"Karahoca","year":"2013","journal-title":"Clin. Epigenet."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Demidenko, E., and Miller, T.W. (2019). Statistical Determination of Synergy Based on Bliss Definition of Drugs Independence. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0224137"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/14737140.2025.2544859","article-title":"Oral Decitabine and Cedazuridine for the Treatment of Myelodysplastic Syndromes: An Integrated Review of Clinical, Economic and Patient-Centered Evidence","volume":"25","author":"Zeidan","year":"2025","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s12325-021-01948-8","article-title":"The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia","volume":"39","author":"Santini","year":"2022","journal-title":"Adv. Ther."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/9\/826\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T10:19:16Z","timestamp":1777630756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/9\/826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["cells15090826"],"URL":"https:\/\/doi.org\/10.3390\/cells15090826","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}